Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: Cellular senescence and metabolic reprogramming model based on bulk/single-cell RNA sequencing reveals PTGER4 as a therapeutic target for ccRCC

Fig. 6

Sensitivity of clear cell renal cell carcinoma (ccRCC) patients with different senescence-metabolism-related risk score (SeMRM) subgroups to drugs. (A) Gene set enrichment analysis (GSEA) showed that drug metabolism-related gene sets were enriched in high or low SeMRM subgroups (p < 0. 05, false discovery rate (FDR) < 0. 25). (B) Sensitivity estimation of current clinically preferred drugs for patients with advanced renal cell carcinoma with high and low SeMRM risk. (C, D) to predict the sensitivity of potential drugs to advanced renal cell carcinoma in SeMRM high-risk and low-risk patients

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us